ClinicalTrials.gg
CompletedNCT03695185Updated Mar 15, 2023Results posted

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

A Phase 2 interventional study of Ravagalimab 600 mg and Ravagalimab 300 mg in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 34 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Colitis, Ulcerative by AbbVie — 6 open to participants now, 13 under way, 5 of them phase 3. Colitis, Ulcerative · AbbVie.

Enrollment
24th of 31
42 · median 156
Started
2019
the only one that year
Phase 2
5 of 53
1 open now
Registered
30th of 53
by date

Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 24th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 30th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 53 studies in Colitis, Ulcerative by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Colitis, Ulcerative by AbbVie, or all of them as a file.
02

Study summary

Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

Keywords

  • Ulcerative Colitis (UC)
  • ABBV-323
  • Ravagalimab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must voluntarily sign and date an , approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures.
  • Diagnosis of UC for at least 3 months prior to Baseline. Appropriate documentation of results consistent with the diagnosis of UC in the assessment of the Investigator, must be available.
  • Participant meets the following disease activity criteria: Active UC with an Adapted Mayo score of 5 to 9 points and endoscopic subscore of 2 to 3 (confirmed by central review).
  • History of inadequate response, loss of response, or intolerance to one or more of the approved biologic therapies: infliximab, adalimumab, golimumab, vedolizumab, and/or tofacitinib (Note: If tofacitinib was received in a clinical trial, subject must have received open-label drug).

Exclusion criteria

Exclusion Criteria:

  • Participant having an active, chronic, or recurrent infection that based on Investigator's clinical assessment makes the participant an unsuitable candidate for the study.
  • Participant having any except for successfully treated non- cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix.
  • Participant with history of dysplasia of the gastrointestinal tract or evidence of dysplasia in any performed during the screening endoscopy other than completely removed low-grade dysplastic lesions.
  • Laboratory values not meeting the following criteria : Serum (AST) and alanine transaminase (ALT) \<= 2* (ULN); Total white blood cell (WBC) count >= 3.0*10\^9/L.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Ravagalimab 600 mg/300 mg

    Participants received ravagalimab 600 mg intravenous (IV) at Week 0 followed by ravagalimab 300 mg subcutaneously (SC) at Weeks 2, 4, 6, 8, and 10 in a 12-week Induction Period. Participants who achieved clinical response per partial adapted Mayo score at Week 12 of the Induction Period entered the Maintenance Period to receive ravagalimab 300 mg SC every other week (EOW) from Week 12 through Week 102.

    Drug: Ravagalimab 600 mg · Drug: Ravagalimab 300 mg

Interventions

  • Ravagalimab 600 mg was administered intravenously (IV).

    Also known as: ABBV-323

  • Ravagalimab 300 mg was administered subcutaneously (SC).

    Also known as: ABBV-323

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Endoscopic Improvement During Induction Period

    Endoscopic Improvement is defined as Mayo endoscopic subscore of 0 or 1. Mayo endoscopic score is classified as 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern); 2=Moderate disease (marked erythema, absent vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration). Higher score indicates worsening of the disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

    Time frame: At Week 8

Secondary outcomes

  1. Percentage of Participants With Clinical Remission Per Adapted Mayo Score During Induction Period

    Clinical remission per Adapted Mayo score is defined as stool frequency subscore (SFS) \<=1, and not greater than baseline, rectal bleeding subscore (RBS) = 0, and endoscopic subscore \<=1. The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal), Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed), Endoscopic subscore confirmed by central reader, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

    Time frame: At Week 8

  2. Percentage of Participants With Clinical Response Per Adapted Mayo Score During Induction Period

    Clinical response per Adapted Mayo score is defined as the decrease from Baseline \>= 2 points and \>= 30%, PLUS a decrease in RBS \>=1 or an absolute RBS \<=1. The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal), Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed), Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 with higher scores representing more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

    Time frame: At Week 8

  3. Percentage of Participants With Clinical Response Per Partial Adapted Mayo Score

    Clinical response per Partial Adapted Mayo score is defined as decrease from baseline \>=1 points and \>=30%, PLUS a decrease in RBS \>= 1 or an absolute RBS \<=1. The Partial Adapted Mayo Score is a composite score of UC disease activity based on the following 2 subscores: SFS, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal); RBS, scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Adapted Mayo score ranges from 0 to 6 with higher scores representing more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

    Time frame: Up to Week 8

  4. Percentage of Participants With Clinical Remission Per Full Mayo Score During Induction Period in Participants With a Full Mayo Score of 6 to 12 at Baseline

    Clinical Remission per full Mayo score is defined as Full Mayo score \<=2 with no subscore \> 1. The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Endoscopies were assessed by a central reader. Negative changes indicate improvement. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to the nearest whole integer.

    Time frame: At Week 8

  5. Percentage of Participants With Endoscopic Remission During Induction Period

    Endoscopic remission is defined as Mayo endoscopic subscore = 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). Higher score indicates worsening of the disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to the nearest whole integer.

    Time frame: At Week 8

07

Results

Posted Mar 15, 2023

Participant flow

A total of 42 participants were enrolled in the Induction Period to receive ravagalimab 600 mg intravenously (IV) followed by ravagalimab 300 mg subcutaneously (SC) up to Week 12. Participants who completed the Induction Period and achieved clinical response per partial adapted Mayo score at Week 12 entered the Maintenance Period to receive ravagalimab 300 mg SC up to Week 102.

Induction Period (Week 0 to Week 12)
Participant flow — Induction Period (Week 0 to Week 12)
MilestoneRavagalimab 600 mg/300 mg
Started42
Completed29
Not completed13
Withdrew: Adverse event1
Withdrew: Withdrew consent2
Withdrew: Lack of efficacy10
Maintenance Period (Week 12 to Week 102)
Participant flow — Maintenance Period (Week 12 to Week 102)
MilestoneRavagalimab 600 mg/300 mg
Started29
Completed1
Not completed28
Withdrew: Withdrew consent3
Withdrew: Lack of efficacy2
Withdrew: Reason not specified23

Outcome measures

PrimaryPercentage of Participants With Endoscopic Improvement During Induction Period

Endoscopic Improvement is defined as Mayo endoscopic subscore of 0 or 1. Mayo endoscopic score is classified as 0=Normal or inactive disease; 1=Mild disease (erythema, decreased vascular pattern); 2=Moderate disease (marked erythema, absent vascular pattern, friability, erosions); 3=Severe disease (spontaneous bleeding, ulceration). Higher score indicates worsening of the disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Improvement During Induction Period
percentage of participantsRavagalimab 600 mg/300 mg
Percentage of Participants With Endoscopic Improvement During Induction Period18.0
SecondaryPercentage of Participants With Clinical Remission Per Adapted Mayo Score During Induction Period

Clinical remission per Adapted Mayo score is defined as stool frequency subscore (SFS) \<=1, and not greater than baseline, rectal bleeding subscore (RBS) = 0, and endoscopic subscore \<=1. The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal), Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed), Endoscopic subscore confirmed by central reader, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per Adapted Mayo Score During Induction Period
percentage of participantsRavagalimab 600 mg/300 mg
Percentage of Participants With Clinical Remission Per Adapted Mayo Score During Induction Period9.5
SecondaryPercentage of Participants With Clinical Response Per Adapted Mayo Score During Induction Period

Clinical response per Adapted Mayo score is defined as the decrease from Baseline \>= 2 points and \>= 30%, PLUS a decrease in RBS \>=1 or an absolute RBS \<=1. The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal), Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed), Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 with higher scores representing more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response Per Adapted Mayo Score During Induction Period
percentage of participantsRavagalimab 600 mg/300 mg
Percentage of Participants With Clinical Response Per Adapted Mayo Score During Induction Period40.2
SecondaryPercentage of Participants With Clinical Response Per Partial Adapted Mayo Score

Clinical response per Partial Adapted Mayo score is defined as decrease from baseline \>=1 points and \>=30%, PLUS a decrease in RBS \>= 1 or an absolute RBS \<=1. The Partial Adapted Mayo Score is a composite score of UC disease activity based on the following 2 subscores: SFS, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal); RBS, scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Adapted Mayo score ranges from 0 to 6 with higher scores representing more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.

Time frame:
Up to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response Per Partial Adapted Mayo Score
percentage of participantsRavagalimab 600 mg/300 mg
Percentage of Participants With Clinical Response Per Partial Adapted Mayo Score57.1
SecondaryPercentage of Participants With Clinical Remission Per Full Mayo Score During Induction Period in Participants With a Full Mayo Score of 6 to 12 at Baseline

Clinical Remission per full Mayo score is defined as Full Mayo score \<=2 with no subscore \> 1. The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Endoscopies were assessed by a central reader. Negative changes indicate improvement. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to the nearest whole integer.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission Per Full Mayo Score During Induction Period in Participants With a Full Mayo Score of 6 to 12 at Baseline
percentage of participantsRavagalimab 600 mg/300 mg
Percentage of Participants With Clinical Remission Per Full Mayo Score During Induction Period in Participants With a Full Mayo Score of 6 to 12 at Baseline7.5
SecondaryPercentage of Participants With Endoscopic Remission During Induction Period

Endoscopic remission is defined as Mayo endoscopic subscore = 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). Higher score indicates worsening of the disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to the nearest whole integer.

Time frame:
At Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Remission During Induction Period
percentage of participantsRavagalimab 600 mg/300 mg
Percentage of Participants With Endoscopic Remission During Induction Period0.0

Adverse events

Collected over From first dose of study drug up to safety follow up visit (up to approximately 116 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Period: Ravagalimab 600 mg/300 mg0/42 (0%)2/42 (4.8%)15/42 (35.7%)
Maintenance Period: Ravagalimab 300 mg0/29 (0%)2/29 (6.9%)19/29 (65.5%)
Most frequent serious events
Most frequent serious events
EventInduction Period: Ravagalimab 600 mg/300 mgMaintenance Period: Ravagalimab 300 mg
LARGE INTESTINE INFECTIONInfections and infestations0/421/29
ARTHRALGIAMusculoskeletal and connective tissue disorders0/421/29
COLITIS ULCERATIVEGastrointestinal disorders1/420/29
PERIRECTAL ABSCESSInfections and infestations1/420/29
Most frequent other events
Showing 10 of 18
Most frequent other events
EventInduction Period: Ravagalimab 600 mg/300 mgMaintenance Period: Ravagalimab 300 mg
ARTHRALGIAMusculoskeletal and connective tissue disorders0/426/29
PYREXIAGeneral disorders2/424/29
HEADACHENervous system disorders2/424/29
FATIGUEGeneral disorders2/423/29
COVID-19Infections and infestations0/423/29
BACK PAINMusculoskeletal and connective tissue disorders1/423/29
PARAESTHESIANervous system disorders1/423/29
PRURITUSSkin and subcutaneous tissue disorders1/423/29
HAEMORRHOIDSGastrointestinal disorders3/421/29
NAUSEAGastrointestinal disorders3/421/29

Baseline characteristics

Full Analysis Set (FAS) included all enrolled participants who received at least 1 dose of ravagalimab and was used for all baseline and efficacy analyses.

Age, Continuous
Age, Continuous(years)Ravagalimab 600 mg/ 300 mg
Mean42.3 ± 14.41
Sex: Female, Male
Sex: Female, Male(Participants)Ravagalimab 600 mg/ 300 mg
Female17
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ravagalimab 600 mg/ 300 mg
Hispanic or Latino5
Not Hispanic or Latino37
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ravagalimab 600 mg/ 300 mg
Race — White39
Race — Non-White3
08

Study locations

34 sites
  • Banner University Medical Cent /ID# 208392
    Tucson, Arizona 85724, United States
  • Meridian Investigator Network /ID# 204646
    Huntington Beach, California 92648-5994, United States
  • Meridian Investigator Network /ID# 218568
    Lakewood, California 90712, United States
  • TLC Clinical Research Inc /ID# 206626
    Los Angeles, California 90048, United States
  • Orange County Institute of Gastroenterology and Endoscopy /ID# 207405
    Mission Viejo, California 92691-6306, United States
  • UC Davis Medical Center /ID# 209402
    Sacramento, California 95817, United States
  • The University of Chicago DCAM /ID# 207086
    Chicago, Illinois 60637, United States
  • Affinity Clinical Research /ID# 206211
    Oak Brook, Illinois 60523-1245, United States
  • Univ New Mexico /ID# 208817
    Albuquerque, New Mexico 87131, United States
  • Penn Presbyterian Medical Center /ID# 206826
    Philadelphia, Pennsylvania 19104-2640, United States
  • Vanderbilt University Medical Center /ID# 204670
    Nashville, Tennessee 37232-0011, United States
  • Clinical Associates in Research Therapeutics of America, LLC /ID# 204689
    San Antonio, Texas 78212, United States
  • Mount Sinai Hospital /ID# 206180
    Toronto, Ontario M5G 1X5, Canada
  • Chu de Nice-Hopital L'Archet Ii /Id# 208131
    Nice, Alpes-Maritimes 06200, France
  • Hopital Beaujon /ID# 208129
    Clichy, Ile-de-France 92110, France
  • CHRU Nancy - Hôpitaux de Brabois /ID# 208133
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54500, France
  • Universitaetsklinikum Frankfurt /ID# 207569
    Frankfurt am Main, Hessen 60590, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 207571
    Kiel, Schleswig-Holstein 24105, Germany
  • Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 207570
    Berlin, 10117, Germany
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 221576
    Szeged, Csongrad 6725, Hungary
  • Debreceni Egyetem Klinikai Kozpont /ID# 221952
    Debrecen, 4032, Hungary
  • University of Catanzaro /ID# 204546
    Catanzaro, Calabria 88100, Italy
  • Presidio Columbus-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Un /ID# 204549
    Rome, Roma 00168, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 208504
    Milan, 20122, Italy
  • Kyungpook National University Hospital /ID# 209912
    Daegu, 41944, Korea, Republic of
  • Yeungnam University Medical Center /ID# 210447
    Daegu, 42415, Korea, Republic of
  • Maastricht Universitair Medisch Centrum /ID# 204428
    Maastricht, 6229 HX, Netherlands
  • Franciscus Gasthuis & Vlietland /ID# 206976
    Rotterdam, 3045 PM, Netherlands
  • Elisabeth Tweesteden Ziekenhuis /ID# 206272
    Tilburg, 5022 GC, Netherlands
  • Hospital Santa Creu i Sant Pau /ID# 213259
    Barcelona, 08041, Spain
  • Hospital General Universitario Gregorio Maranon /ID# 204504
    Madrid, 28007, Spain
  • Hospital Universitario La Paz /ID# 210065
    Madrid, 28046, Spain
  • NHS Greater Glasgow and Clyde /ID# 206574
    Glasgow, Scotland G12 0XH, United Kingdom
  • Belfast Health and Social Care Trust /ID# 206744
    Belfast, BT9 7AB, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Apr 2021, 24 months.

Results were first posted in Mar 2023, 1 year 11 months after primary completion. A results delay was requested in Mar 2022.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 24 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2018
First posted
Oct 4, 2018
StartActual
Mar 26, 2019
Primary completionActual
Apr 5, 2021
CompletionActual
Jan 10, 2022
Results delay requested
Mar 10, 2022
Results first posted
Mar 15, 2023
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03695185
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 4, 2018
Start date
Mar 26, 2019
Primary completion
Apr 5, 2021
Completion
Jan 10, 2022
Results posted
Mar 15, 2023
Last update
Mar 15, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravagalimab

Start the discussion